KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) FCF Margin (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed FCF Margin for 17 consecutive years, with 12.83% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin fell 2007.0% to 12.83% in Q4 2025 year-over-year; TTM through Dec 2025 was 26.65%, a 221.0% decrease, with the full-year FY2025 number at 26.65%, down 221.0% from a year prior.
  • FCF Margin was 12.83% for Q4 2025 at Bristol Myers Squibb, down from 49.02% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 49.02% in Q3 2025 to a low of 12.83% in Q4 2025.
  • A 5-year average of 28.48% and a median of 29.77% in 2022 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: skyrocketed 2292bps in 2021, then crashed -2007bps in 2025.
  • Bristol Myers Squibb's FCF Margin stood at 31.18% in 2021, then fell by -17bps to 25.95% in 2022, then soared by 32bps to 34.17% in 2023, then fell by -4bps to 32.9% in 2024, then plummeted by -61bps to 12.83% in 2025.
  • Per Business Quant, the three most recent readings for BMY's FCF Margin are 12.83% (Q4 2025), 49.02% (Q3 2025), and 28.98% (Q2 2025).